CompletedNot Applicable

The Role of CVP and EF in Patients With Cardio-renal Syndromes

11 participantsStarted 2015-09

Plain-language summary

The aim of the study is to explore association between increased central venous pressure, Ejection Fraction and renal dysfunction (eGFR) in patients with Cardio-Renal Syndromes type 1 and 2. The pilot study was set to provide the expected correlation coefficient for a sample size determination of the subsequent study.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HF (NYHA class I - IV, with preserved and reduced EF) and reduced GFR (Cardio-Renal Syndromes 1 and 2) Exclusion Criteria: * Independent risk factors for renal impairment (e.g. diabetes, sepsis) * Primary nephropathy or secondary nephropathy due to diseases other than HF

What they're measuring

renal impairment (defined as a Glomerular Filtration Rate less than 60 mL/min per 1.73 m2)

Timeframe: through study completion, an average of 1 year

Trial details

NCT IDNCT02792387

SponsorTbilisi State University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Heart Failure trials